556 related articles for article (PubMed ID: 33975804)
1. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease.
Lim S; Kim JW; Targher G
Trends Endocrinol Metab; 2021 Jul; 32(7):500-514. PubMed ID: 33975804
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
[TBL] [Abstract][Full Text] [Related]
3. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome.
Abenavoli L; Scarlata GGM; Scarpellini E; Boccuto L; Spagnuolo R; Tilocca B; Roncada P; Luzza F
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984595
[TBL] [Abstract][Full Text] [Related]
4. MAFLD as part of systemic metabolic dysregulation.
Zhao J; Liu L; Cao YY; Gao X; Targher G; Byrne CD; Sun DQ; Zheng MH
Hepatol Int; 2024 Apr; ():. PubMed ID: 38594474
[TBL] [Abstract][Full Text] [Related]
5. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
[TBL] [Abstract][Full Text] [Related]
6. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.
Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M
Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
8. Metabolic dysfunction-associated fatty liver disease is an early predictor for testosterone deficiency in aging men without metabolic syndrome.
Liu CC; Huang SP; Lee YC; Lee CH; Huang TY; Geng JH; Chang CW; Lin CY; Juan YS; Wu WJ; Hsieh TJ
Front Endocrinol (Lausanne); 2023; 14():1252774. PubMed ID: 37854195
[TBL] [Abstract][Full Text] [Related]
9. Role of Insulin Resistance in MAFLD.
Sakurai Y; Kubota N; Yamauchi T; Kadowaki T
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923817
[TBL] [Abstract][Full Text] [Related]
10. Metabolic dysfunction-associated fatty liver disease (MAFLD) as a more accurate name for NAFLD - common aspects of pathogenesis.
Nováková B
Cas Lek Cesk; 2022; 161(2):65-71. PubMed ID: 35728960
[TBL] [Abstract][Full Text] [Related]
11. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
[TBL] [Abstract][Full Text] [Related]
12. Fatty liver with metabolic disorder, such as metabolic dysfunction-associated fatty liver disease, indicates high risk for developing diabetes mellitus.
Miyake T; Matsuura B; Furukawa S; Ishihara T; Yoshida O; Miyazaki M; Watanebe K; Shiomi A; Nakaguchi H; Yamamoto Y; Koizumi Y; Tokumoto Y; Hirooka M; Takeshita E; Kumagi T; Abe M; Ikeda Y; Iwata T; Hiasa Y
J Diabetes Investig; 2022 Jul; 13(7):1245-1252. PubMed ID: 35167194
[TBL] [Abstract][Full Text] [Related]
13. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy.
Xian YX; Weng JP; Xu F
Chin Med J (Engl); 2020 Dec; 134(1):8-19. PubMed ID: 33323806
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).
Zhao Y; Zhou Y; Wang D; Huang Z; Xiao X; Zheng Q; Li S; Long D; Feng L
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139341
[TBL] [Abstract][Full Text] [Related]
15. [NAFLD renaming to MAFLD, MASLD: background, similarities, differences, and countermeasures].
Fan JG; Li XY
Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):789-792. PubMed ID: 37723058
[TBL] [Abstract][Full Text] [Related]
16. Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses.
Mori K; Tanaka M; Hosaka I; Mikami T; Endo K; Hanawa N; Ohnishi H; Furuhashi M
Hypertens Res; 2023 May; 46(5):1110-1121. PubMed ID: 36717630
[TBL] [Abstract][Full Text] [Related]
17. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.
Yuan X; Wang X; Wu S; Chen S; Wang Y; Wang J; Lu Y; Sun Y; Fu Q; Wang L
Hepatobiliary Surg Nutr; 2023 Oct; 12(5):671-681. PubMed ID: 37886198
[TBL] [Abstract][Full Text] [Related]
18. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
[TBL] [Abstract][Full Text] [Related]
19. Association of metabolic dysfunction-associated fatty liver disease with kidney disease.
Wang TY; Wang RF; Bu ZY; Targher G; Byrne CD; Sun DQ; Zheng MH
Nat Rev Nephrol; 2022 Apr; 18(4):259-268. PubMed ID: 35013596
[TBL] [Abstract][Full Text] [Related]
20. Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.
Ore A; Akinloye OA
Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
